Syncom Formulations cash falls as investments and borrowing rise

Syncom Formulations (India) Limited ended 30 September 2026 with cash and cash equivalents of Rs 33.65 lakh, down from Rs 5.1475 crore at 31 March 2026, after Rs 57.5585 crore of net investing outflow exceeded Rs 39.1199 crore of operating cash generation despite Rs 13.6276 crore of financing inflow.

Why did Syncom Formulations’ cash balance decline?

Syncom Formulations’ cash balance declined because its investing outflow exceeded the combined cash generated from operations and financing in the six months ended 30 September 2026. Cash and cash equivalents decreased by Rs 4.811 crore during the period, falling from Rs 5.1475 crore at the start to Rs 33.65 lakh at the end.

Net cash from operating activities was Rs 39.1199 crore after income-tax payments of Rs 16.3907 crore. Cash generated from operations before tax was Rs 55.5106 crore, built from operating profit before working-capital changes of Rs 58.1756 crore and a working-capital outflow of Rs 2.6649 crore.

Working-capital movements differed from the year ended 31 March 2026, when they generated Rs 10.0716 crore of cash. In the latest six-month period, lower inventory contributed Rs 20.4707 crore, but trade payables used Rs 29.4562 crore and the increase in trade receivables used Rs 13.0988 crore.

How much did Syncom Formulations invest in the half year?

Syncom Formulations recorded Rs 57.5585 crore of net cash outflow from investing activities in the six months ended 30 September 2026, principally because the cash-flow statement reported a Rs 61.0909 crore change in investments. That investing outflow exceeded the Rs 50.6227 crore outflow reported for the full year ended 31 March 2026.

Current investments increased to Rs 170.9801 crore at 30 September 2026 from Rs 106.5164 crore at 31 March 2026, a rise of Rs 64.4637 crore. Non-current investments also rose, to Rs 2.5958 crore from Rs 2.5343 crore, while the cash-flow investment movement and the balance-sheet increase are separately reported measures.

Property, plant and equipment, intangible assets and capital work in progress accounted for a Rs 5.6579 crore cash outflow in the investing section. Other non-current assets used Rs 6.3204 crore, while investment property produced a Rs 80.75 lakh inflow and other income contributed Rs 13.7754 crore within investing activities.

How much did Syncom Formulations’ borrowings increase?

Syncom Formulations’ current borrowings increased by Rs 14.8779 crore to Rs 16.3521 crore at 30 September 2026 from Rs 1.4742 crore at 31 March 2026. The cash-flow statement also records Rs 14.8779 crore from borrowings during the six-month period.

Financing activities supplied Rs 13.6276 crore of cash in the latest period, compared with an outflow of Rs 3.0211 crore in the year ended 31 March 2026. The latest inflow reflected the increase in borrowings, partly offset by Rs 65.18 lakh of finance costs and a Rs 59.85 lakh reduction in long-term liabilities.

Finance costs were Rs 65.18 lakh in the six months ended 30 September 2026, compared with Rs 51.57 lakh in the corresponding six months ended 30 September 2025. In the September 2026 quarter alone, finance costs were Rs 40.73 lakh, compared with Rs 24.45 lakh in the June 2026 quarter.

What changed in Syncom Formulations’ working-capital assets?

Syncom Formulations shifted balance-sheet resources towards current investments while cash, inventory and other current assets decreased at 30 September 2026. Total assets rose to Rs 573.2236 crore from Rs 533.8452 crore at 31 March 2026, alongside the Rs 64.4637 crore increase in current investments.

Inventories decreased to Rs 42.4078 crore from Rs 62.8785 crore, consistent with the positive Rs 20.4707 crore inventory cash-flow movement. Trade receivables rose to Rs 123.6036 crore from Rs 110.5048 crore, corresponding to the Rs 13.0988 crore use of cash reported in operating working capital.

Other current assets fell to Rs 11.1787 crore from Rs 33.2729 crore, generating a Rs 21.9416 crore operating cash inflow. Bank balances other than cash equivalents were Rs 1.2292 crore at 30 September 2026, while current deposits were Rs 3.9674 crore; both are reported separately from the Rs 33.65 lakh cash-and-cash-equivalents balance.

What do Syncom Formulations’ operating results show?

Syncom Formulations reported revenue from operations of Rs 267.6713 crore for the six months ended 30 September 2026, compared with Rs 238.6191 crore in the corresponding period a year earlier. Profit after tax increased to Rs 51.50 crore from Rs 32.3555 crore, while operating cash generation was Rs 39.1199 crore after tax and working-capital movements.

Profit before tax was Rs 68.2799 crore in the six months ended 30 September 2026, compared with Rs 42.3289 crore in the corresponding period of 2025. Finance costs rose to Rs 65.18 lakh from Rs 51.57 lakh over the same comparison, while the filing reports no lender names, repayment schedule, interest-rate terms or stated borrowing purpose.

Other equity increased to Rs 375.8375 crore at 30 September 2026 from Rs 320.9883 crore at 31 March 2026, while equity share capital remained Rs 94 crore. Total current trade payables declined to Rs 44.934 crore from Rs 74.3902 crore, including Rs 7.2874 crore due to micro and small enterprises at the September balance-sheet date.

Conclusion

Syncom Formulations generated Rs 39.1199 crore of operating cash during the six months ended 30 September 2026, but its Rs 57.5585 crore investing outflow, led by the investment movement, reduced cash and cash equivalents to Rs 33.65 lakh. Borrowings increased by Rs 14.8779 crore and provided most of the Rs 13.6276 crore financing inflow, while current investments reached Rs 170.9801 crore.

The next financial statements will show whether current investments of Rs 170.9801 crore are reduced, whether receivables of Rs 123.6036 crore are collected and how current borrowings of Rs 16.3521 crore change. The filing does not disclose a borrowing repayment schedule, investment plan or liquidity target, leaving those matters unresolved at 30 September 2026.